Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
- Status
- TERMINATED
- Phase
- PHASE2
Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
- Status
- COMPLETED
- Phase
- PHASE1
Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
- Status
- COMPLETED
- Phase
- PHASE2